Welcome : Guest

Emphasis on Gynecological Health among Modern Women and Widespread Awareness Campaigns to Drive the Global Endometriosis Market

Published: January 2018


  • Code: MCP-6433
  • Pages: 181
  • Tables: 33
  • Companies: 38


The global market for Endometriosis Drugs is projected to reach US$2.6 billion by 2022, driven by growing patient and social awareness over this poorly understood disease. Growing awareness of the disease as the primary cause of infertility is helping result in increased diagnosis, early interventions, and improved prognosis. Better understanding and knowledge over the medical condition is also helping in the gradual dissipation of the stigma associated with the disease, leading to increased willingness to obtain medical help. All of these factors are expected to result in a drastic reduction in delayed diagnosis and benefit demand for endometriosis drugs. Future growth in the market will come from the launch of Neurocrine and Abbvies Elagolix, the first oral GnRH (gonadotropin releasing hormone) antagonist, superior to injectable GnRH agonists. The United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 3.4% over the analysis period, led by large population of women in the reproductive age and unmet therapeutic needs for endometriosis; increasing healthcare spending among the affluent, middle class population and the rise of a growing base of empowered healthcare consumers. 

    Summary of Findings

  • Growing Research in the Pathophysiology of Endometriosis to Benefit the Development of Newer and More Potent Drugs
  • Close Association of Endometriosis with Infertility Throws the Emphasis on Early Diagnosis and Prevention of Disease Progression to Reduce Risk of Intractable Infertility
  • The Need for Long-Term Management of Endometriosis: The Cornerstone for Growth in the Endometriosis Drugs Market
  • Research Efforts Focused on Non-Hormonal Therapies for Endometriosis to Spearhead Future Growth in the Market
  • Pain Medications such as Non-Steroidal Anti Inflammatory Drugs (NSAIDs) and Hormonal Therapies Continue to Dominate Endometriosis Treatment

    Timeline for Analysis

  • Market Estimates and Forecasts for 2015-2022
  • Historic Review 2009-2014

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, and Rest of World


  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Debiopharm Group
  • Evotec AG


  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable

Interested in our research, you can contact our 24/7 Research Support e-Desk at rsd@strategyr.com